Vera Therapeutics, Inc.
About Vera Therapeutics, Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$299.6M
- Total assets
- $734.7M
- Market cap
- $2.3B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $315.5M
- Operating income
- -$315.5M
- Income tax
- $1.0K
- Net income
- -$299.6M
- EPS (basic)
- $-4.66
- EPS (diluted)
- $-4.66
Balance sheet
- Total assets
- $734.7M
- Current assets
- $728.9M
- Total liabilities
- $130.2M
- Current liabilities
- $53.5M
- Shareholders’ equity
- $604.5M
Cash flow
- Operating cash flow
- -$241.1M
- Investing cash flow
- $194.3M
- Financing cash flow
- $308.9M
- Net cash flow
- $262.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.3B
- EPS (diluted)
- $-4.66
- Shares outstanding
- 73.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 14, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $299.6M.
- Trading 43% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Vera Therapeutics, Inc..
Write a review
News about Vera Therapeutics, Inc.
News & sentiment via Polygon.io
